Journal Watch · Science Translational Medicine · 2026

IgA is necessary and sufficient to prevent norovirus infection in mice.

Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.

Ökten AB, Filler RB, Kung JL et al.Science Translational Medicine3 min readPharma relevance 70/100

DOI: 10.1126/scitranslmed.aeb4878PMID: 42341085Study type: preclinical (animal / model) study

TL;DR

Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.

Key findings

  • In contrast, prophylactic delivery of dimeric anti-norovirus IgA via mRNA lipid nanoparticles confers sterilizing immunity.
  • Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.

What they did

Robust intestinal IgA production requires at least 4 weeks of enteric infection, consistent with kinetics of human norovirus RNA clearance. Systemic vaccination elicits high titers of neutralizing serum IgG but fails to prevent enteric norovirus infection, phenocopying a recent human norovirus vaccine failure.

Full abstract (original)

Background: Human norovirus is the leading cause of viral gastroenteritis, yet effective vaccines and therapeutics remain elusive. Using murine norovirus as a model, we found that mucosal immunoglobulin A (IgA) is both necessary and sufficient for protection against infection, whereas CD8<sup>+</sup> T cells are dispensable.

What they did: Robust intestinal IgA production requires at least 4 weeks of enteric infection, consistent with kinetics of human norovirus RNA clearance. Systemic vaccination elicits high titers of neutralizing serum IgG but fails to prevent enteric norovirus infection, phenocopying a recent human norovirus vaccine failure.

Results & conclusions: In contrast, prophylactic delivery of dimeric anti-norovirus IgA via mRNA lipid nanoparticles confers sterilizing immunity. Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.

Abstract © the authors / Science Translational Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/scitranslmed.aeb4878 · PubMed 42341085.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Science Translational Medicine study find?

Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.

What type of study is this?

It is a preclinical (animal / model) study, published in Science Translational Medicine in 2026. Robust intestinal IgA production requires at least 4 weeks of enteric infection, consistent with kinetics of human norovirus RNA clearance.

Where can I read the original paper?

The original is at the publisher via DOI 10.1126/scitranslmed.aeb4878. PubMed ID: 42341085. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ökten AB, Filler RB, Kung JL et al.. IgA is necessary and sufficient to prevent norovirus infection in mice.. Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.aeb4878.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/iga-is-necessary-and-sufficient-to-prevent-norovirus-infection-in-mice-eb4878/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides